Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells

John W. Barrett, Lindsay R. Alston, Fuan Wang, Marianne M. Stanford, Philippe Alexandre Gilbert, Xiujuan Gao, June Jimenez, Danielle Villeneuve, Peter Forsyth, Douglas McFadden

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The authors have recently demonstrated that wild-type myxoma virus (MV) tagged with gfp (vMyxgfp) can generate a tumor-specific infection that productively infects and clears human tumor-derived xenografts when injected intratumorly into human gliomas transplanted into immunodeficient mice (Lun et al, 2005). To expand the understanding of MV tropism in cancer cells from a specific tissue lineage, the authors have screened a series of human glioma cells (U87, U118, U251, U343, U373) for myxoma virus replication and oncolysis. To assess the viral tropism determinants for these infections, the authors have screened myxoma virus knockout constructs that have been deleted for specific host range genes (M-T2, M-T4, M-T5, M11L, and M063), as well as a control MV gene knockout construct with no known host range function (vMyx135KO) but is highly attenuated in rabbits. The authors report wide variation in the ability of various vMyx-hrKOs to replicate and spread in the human glioma cells as measured by early and late viral gene expression. This differential ability to support vMyx-hrKO productive viral replication is consistent with levels of endogenous activated Akt in the various gliomas. The authors have identified one vMyx-hrKO virus (vMyx63KO) and one nonhost range knockout construct (vMyx135KO) that appear to replicate in the gliomas even more efficiently than the wild-type virus and that reduce the viability of the infected gliomas. These knockout viruses also inhibit the proliferation of gliomas in a manner similar to the wild-type virus. Together these data, as well as the fact that these knockout viruses are attenuated in their natural hosts, may represent environmentally safer candidate oncolytic viruses for usage in human trials.

Original languageEnglish (US)
Pages (from-to)549-560
Number of pages12
JournalJournal of NeuroVirology
Volume13
Issue number6
DOIs
StatePublished - Nov 1 2007
Externally publishedYes

Fingerprint

Myxoma virus
Host Specificity
Glioma
Viruses
Viral Tropism
Oncolytic Viruses
Microbial Viability
Neoplasms
Gene Knockout Techniques
Tropism
Viral Genes
Virus Replication
Infection
Heterografts
Rabbits
Gene Expression

Keywords

  • Glioblastoma
  • Host range
  • Poxvirus
  • Tropism
  • Virotherapy

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Virology

Cite this

Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells. / Barrett, John W.; Alston, Lindsay R.; Wang, Fuan; Stanford, Marianne M.; Gilbert, Philippe Alexandre; Gao, Xiujuan; Jimenez, June; Villeneuve, Danielle; Forsyth, Peter; McFadden, Douglas.

In: Journal of NeuroVirology, Vol. 13, No. 6, 01.11.2007, p. 549-560.

Research output: Contribution to journalArticle

Barrett, JW, Alston, LR, Wang, F, Stanford, MM, Gilbert, PA, Gao, X, Jimenez, J, Villeneuve, D, Forsyth, P & McFadden, D 2007, 'Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells', Journal of NeuroVirology, vol. 13, no. 6, pp. 549-560. https://doi.org/10.1080/13550280701591526
Barrett, John W. ; Alston, Lindsay R. ; Wang, Fuan ; Stanford, Marianne M. ; Gilbert, Philippe Alexandre ; Gao, Xiujuan ; Jimenez, June ; Villeneuve, Danielle ; Forsyth, Peter ; McFadden, Douglas. / Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells. In: Journal of NeuroVirology. 2007 ; Vol. 13, No. 6. pp. 549-560.
@article{c1ad4ddbd237425f9805c90a7d9dc44e,
title = "Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells",
abstract = "The authors have recently demonstrated that wild-type myxoma virus (MV) tagged with gfp (vMyxgfp) can generate a tumor-specific infection that productively infects and clears human tumor-derived xenografts when injected intratumorly into human gliomas transplanted into immunodeficient mice (Lun et al, 2005). To expand the understanding of MV tropism in cancer cells from a specific tissue lineage, the authors have screened a series of human glioma cells (U87, U118, U251, U343, U373) for myxoma virus replication and oncolysis. To assess the viral tropism determinants for these infections, the authors have screened myxoma virus knockout constructs that have been deleted for specific host range genes (M-T2, M-T4, M-T5, M11L, and M063), as well as a control MV gene knockout construct with no known host range function (vMyx135KO) but is highly attenuated in rabbits. The authors report wide variation in the ability of various vMyx-hrKOs to replicate and spread in the human glioma cells as measured by early and late viral gene expression. This differential ability to support vMyx-hrKO productive viral replication is consistent with levels of endogenous activated Akt in the various gliomas. The authors have identified one vMyx-hrKO virus (vMyx63KO) and one nonhost range knockout construct (vMyx135KO) that appear to replicate in the gliomas even more efficiently than the wild-type virus and that reduce the viability of the infected gliomas. These knockout viruses also inhibit the proliferation of gliomas in a manner similar to the wild-type virus. Together these data, as well as the fact that these knockout viruses are attenuated in their natural hosts, may represent environmentally safer candidate oncolytic viruses for usage in human trials.",
keywords = "Glioblastoma, Host range, Poxvirus, Tropism, Virotherapy",
author = "Barrett, {John W.} and Alston, {Lindsay R.} and Fuan Wang and Stanford, {Marianne M.} and Gilbert, {Philippe Alexandre} and Xiujuan Gao and June Jimenez and Danielle Villeneuve and Peter Forsyth and Douglas McFadden",
year = "2007",
month = "11",
day = "1",
doi = "10.1080/13550280701591526",
language = "English (US)",
volume = "13",
pages = "549--560",
journal = "Journal of NeuroVirology",
issn = "1355-0284",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells

AU - Barrett, John W.

AU - Alston, Lindsay R.

AU - Wang, Fuan

AU - Stanford, Marianne M.

AU - Gilbert, Philippe Alexandre

AU - Gao, Xiujuan

AU - Jimenez, June

AU - Villeneuve, Danielle

AU - Forsyth, Peter

AU - McFadden, Douglas

PY - 2007/11/1

Y1 - 2007/11/1

N2 - The authors have recently demonstrated that wild-type myxoma virus (MV) tagged with gfp (vMyxgfp) can generate a tumor-specific infection that productively infects and clears human tumor-derived xenografts when injected intratumorly into human gliomas transplanted into immunodeficient mice (Lun et al, 2005). To expand the understanding of MV tropism in cancer cells from a specific tissue lineage, the authors have screened a series of human glioma cells (U87, U118, U251, U343, U373) for myxoma virus replication and oncolysis. To assess the viral tropism determinants for these infections, the authors have screened myxoma virus knockout constructs that have been deleted for specific host range genes (M-T2, M-T4, M-T5, M11L, and M063), as well as a control MV gene knockout construct with no known host range function (vMyx135KO) but is highly attenuated in rabbits. The authors report wide variation in the ability of various vMyx-hrKOs to replicate and spread in the human glioma cells as measured by early and late viral gene expression. This differential ability to support vMyx-hrKO productive viral replication is consistent with levels of endogenous activated Akt in the various gliomas. The authors have identified one vMyx-hrKO virus (vMyx63KO) and one nonhost range knockout construct (vMyx135KO) that appear to replicate in the gliomas even more efficiently than the wild-type virus and that reduce the viability of the infected gliomas. These knockout viruses also inhibit the proliferation of gliomas in a manner similar to the wild-type virus. Together these data, as well as the fact that these knockout viruses are attenuated in their natural hosts, may represent environmentally safer candidate oncolytic viruses for usage in human trials.

AB - The authors have recently demonstrated that wild-type myxoma virus (MV) tagged with gfp (vMyxgfp) can generate a tumor-specific infection that productively infects and clears human tumor-derived xenografts when injected intratumorly into human gliomas transplanted into immunodeficient mice (Lun et al, 2005). To expand the understanding of MV tropism in cancer cells from a specific tissue lineage, the authors have screened a series of human glioma cells (U87, U118, U251, U343, U373) for myxoma virus replication and oncolysis. To assess the viral tropism determinants for these infections, the authors have screened myxoma virus knockout constructs that have been deleted for specific host range genes (M-T2, M-T4, M-T5, M11L, and M063), as well as a control MV gene knockout construct with no known host range function (vMyx135KO) but is highly attenuated in rabbits. The authors report wide variation in the ability of various vMyx-hrKOs to replicate and spread in the human glioma cells as measured by early and late viral gene expression. This differential ability to support vMyx-hrKO productive viral replication is consistent with levels of endogenous activated Akt in the various gliomas. The authors have identified one vMyx-hrKO virus (vMyx63KO) and one nonhost range knockout construct (vMyx135KO) that appear to replicate in the gliomas even more efficiently than the wild-type virus and that reduce the viability of the infected gliomas. These knockout viruses also inhibit the proliferation of gliomas in a manner similar to the wild-type virus. Together these data, as well as the fact that these knockout viruses are attenuated in their natural hosts, may represent environmentally safer candidate oncolytic viruses for usage in human trials.

KW - Glioblastoma

KW - Host range

KW - Poxvirus

KW - Tropism

KW - Virotherapy

UR - http://www.scopus.com/inward/record.url?scp=37549034204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549034204&partnerID=8YFLogxK

U2 - 10.1080/13550280701591526

DO - 10.1080/13550280701591526

M3 - Article

C2 - 18097886

AN - SCOPUS:37549034204

VL - 13

SP - 549

EP - 560

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

SN - 1355-0284

IS - 6

ER -